San Francisco, 03 January 2030: The Report Comprehensive Metabolic Panel Testing Market Size, Share & Trends Analysis Report By Analytes (K+, Na+, Cl-, CO2, Glucose), By Disease, By End-use (Laboratory, PoC), By Region, And Segment Forecasts, 2023 - 2030

The global comprehensive metabolic panel testing market size is expected to reach USD 20.87 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.1% from 2023 to 2030. The market driven by an increasing global disease burden and the emergence of novel diagnostic products.

Rising prevalence of chronic diseases coupled with increasing need to curb healthcare expenditure are expected to boost the CMP testing market by increasing the demand for early disease diagnosis and regular monitoring. Introduction of technologically advanced products, such as biochips, microarrays, and companion diagnostics, has driven the necessity for early detection of anomalies. CMP testing offers a cost-effective and time-saving method for evaluating 14 analytes for identification, diagnosis, or monitoring of several diseases.

Rising consumer awareness regarding healthcare is one of the major factors anticipated to drive the market for CMP testing. Many organizations worldwide are working toward increasing awareness pertaining to diseases, available treatment options, and benefits of early diagnosis and precautions. For instance, the International Diabetes Foundation and the American Diabetes Association are some of the key organizations that emphasize the urgent need for diagnosing and monitoring diabetes through several awareness campaigns and other modes of advertisement.

The buying behavior of consumers is moderately complex in the comprehensive metabolic panel testing market, due to subtle differences in product prices. The products offered by various market players have been strategically priced to increase competitive rivalry. As the market becomes increasingly competitive, consumer needs are anticipated to reach at an all-time high for improved diagnostics - in terms of safety, efficacy, sensitivity, and specificity.

The medical diagnostics landscape has undergone a paradigm shift over the last few years, driven by the launch of improved diagnostic products and introduction of biomarkers. However, recurrence and disease progression remain high, especially among geriatric patients. Strong unmet needs present a key opportunity to develop breakthrough first-in-class diagnostics in the CMP testing space.

Request sample report of Comprehensive Metabolic Panel Testing Market@ https://www.grandviewresearch.com/industry-analysis/comprehensive-metabolic-panel-cmp-testing-market/request/rs1

Factors such as the rising prevalence of chronic diseases and emphasis on early diagnosis and treatment are expected to drive the demand for CMP testing. The high prevalence of lifestyle-associated diseases, such as obesity, smoking, unhealthy eating habits, and lack of physical activity, are among the factors responsible for increasing the incidence of chronic diseases. The rise in the geriatric population is driving the market as they are more prone to diabetes and cardiovascular diseases. According to World Health Organization (WHO), over 1 billion people are over 60 years and are estimated to reach 1.4 billion by 2030.

Comprehensive Metabolic Panel Testing Market Report Highlights

• The kidney diseases segment accounted for the largest revenue share of 32.71% in 2022, and the segment is driven by a high disease prevalence and maximum utilization of analytes.
• The diabetes segment is expected to grow at the fastest CAGR of 9.9% during the forecast period. Nearly 50% of diabetics remain undiagnosed, presenting a lucrative opportunity for growth for the comprehensive metabolic panel testing market.
• The PoC segment is expected to grow at the fastest CAGR of 9.8% over the forecast period. The PoC CMP tests are driven by their ease of operation, portability, speed of results, and lesser requirement of the sample.
• The laboratories segment accounted for the highest revenue share of 59.97% in 2022, driven by easy availability, high market penetration, increased usage, and clinically significant results.
• Asia Pacific is expected to grow at the highest CAGR of 11.7% over the forecast period, driven by improvements in healthcare infrastructure, a rise in the number of older people, who are more susceptible to chronic illnesses, growth in consumer awareness, a rise in disposable income, and overall economic development.

Diabetes is one of the fastest-growing diseases in the world, widening the patient pool for point-of-Care (PoC) CMP testing. The increasing prevalence of diabetes and cardiovascular, and other target diseases is anticipated to boost the demand for CMP testing over the forecast period. Cardiovascular diseases are fatal and are considered the leading cause of death worldwide. According to WHO, cardiovascular diseases (CVDs) cause 17.9 million deaths annually.

The healthcare industry largely depends on regulatory frameworks established by organizations such as the U.S. Food and Drugs Administration (FDA) and the European Medicines Agency (EMA). Regulatory bodies such as Clinical Laboratory Improvement Amendments (CLIA) regulate the approval of these tests, and government bodies set the fee waiver and the reimbursement for Medicare and Medicaid. The FDA has control over the Laboratory-Developed Tests (LDTs) which refer to in-house clinical laboratories developing tests, delivering efficient and rapid results. For instance, in 2020, the EU4Health program was initiated, health is considered an investment, and the EU4Health program, with a budget of over USD 5.8 billion for 2021-27, is a significant financial support from the EU in the health sector. This program reflects the EU's commitment to prioritizing public health and plays a crucial role in moving toward establishing a European Health Union.

Reimbursement and regulatory bodies in Europe impose stringent laws. Most European manufacturers set the pricing based on the Return on Investment (RoI) and follow value-based pricing. There is an oversupply of testing products that are redundant and a large number of products with similar indications. However, this led to lower pricing, faster processing time, and wider availability of the products.

Comprehensive Metabolic Panel Testing Market Report Scope

The introduction of innovative solutions for enhancing efficiency and minimizing errors is expected to boost the CMP testing market growth over the forecast period. Integrated workflow management systems and database management tools are gaining importance, with companies processing several thousand samples per year. Development and execution of various bioinformatics and data management solutions, coupled with the emergence of automated laboratory systems, indicate a prosperous future for the market.

The COVID-19 pandemic had a significant impact on the comprehensive metabolic panel testing market. Numerous tests have been conducted on blood as a result of the rise in COVID-19; doctors were ordering CMP tests for COVID positive patients to check complete blood count, d-dimer protein, and prothrombin time, and this increase in testing has driven the market for complete metabolic panels overall. According to WHO, 767,984,989 confirmed COVID cases have been registered.